Yahoo!
My Yahoo!
Mail
Sign In
[New User?
Sign Up
]
Finance Home
|
Help
Wednesday, February 10, 2010, 8:48am EST - Canadian Markets open in 42 minutes.
To create a watchlist or portfolio of shares,
Sign-in
or
Register
Finance Home
Investing
Volume Leaders
Local Markets
US Markets
International Markets
Advances & Declines
ETFs
Income Trust News
News & Opinion
Markets
Industry
RSS-My Yahoo!
Personal Finance
Banking & Budgeting
Calculators
Insurance
Retirement
Taxes
My Portfolios
Sign In to Create/Edit My Portfolios
Get Quotes
Symbol Lookup
Exchanges
Alcon Inc. (ACL)
On Feb 9:
157.46 USD
0.00 (0.00%)
MORE ON ACL
Quotes
Summary
Options
Historical Prices
Charts
Interactive
Basic Chart
Technical Chart
News & Info
Headlines
Company Events
Company
Profile
Key Statistics
SEC Filings
Competitors
Industry
Analyst Coverage
Analyst Opinion
Analyst Estimates
Research Reports
Star Analysts
Ownership
Major Holders
Insider Trans.
Insider Roster
Financials
Income Statement
Balance Sheets
Cash Flow
ALCON INC
(NYSE:ACL) Delayed quote data
Last Trade:
157.46 USD
Trade Time:
Feb 9
Change:
0.00 (0.00%)
Prev Close:
157.46
Open:
N/A
Bid:
N/A
Ask:
N/A
1y Target Est:
174.75
Day's Range:
N/A - N/A
52wk Range:
76.03 - 166.71
Volume:
0
Avg Vol
(3m)
:
1,371,340
Market Cap:
47.08B
P/E
(ttm)
:
24.01
EPS
(ttm)
:
6.56
Div & Yield:
3.49 (2.22%)
1d
5d
3m
6m
1y
2y
5y
max
Free Annual Reports
Add ACL to Portfolio
Download Data
HEADLINES
[video] 2 Blowout Earnings Reports
at TheStreet.com
(Tue 3:49pm)
3 Stocks I Saw on TV
TheStreet.com TV
(Mon, Feb 8)
[video] 3 Stocks I Saw on TV
at TheStreet.com
(Fri, Feb 5)
Allergan's Looking Real Pretty Right Now
at CNBC
(Thu, Feb 4)
Two Pharmas
at Forbes.com
(Thu, Feb 4)
NovaBay Pharmaceuticals to Present at the 2010 BIO CEO & Investor Conference
Marketwire
(Thu, Feb 4)
UPDATE - Novartis: no comment on talk may sell Roche stake
at Reuters
(Tue, Feb 2)
Big Chill Hit the Deal Market in January
at The New York Times
(Mon, Feb 1)
Stull, Stull & Brody Files Class Action Suit Against Novartis AG and Nestlé S.A. on Behalf of the Public Minority Shareholders of Alcon, Inc.
Business Wire
(Fri, Jan 29)
Pharma & Biotech Stock Review
Zacks.com
(Thu, Jan 28)
Nice, Novartis, Very Nice
at Motley Fool
(Wed, Jan 27)
More Headlines for ACL...
ANALYST
EPS Est (next year)
(Dec-09)
:
6.72
EPS Est (in 2 years)
(Dec-10)
:
7.43
Avg Rec (current)*:
2.1
PEG Ratio:
1.86
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion
-
Estimates
BUSINESS SUMMARY
Alcon, Inc. engages in the development, manufacture, and marketing of pharmaceuticals, surgical equipment and devices, and consumer eye care products to treat primarily diseases and disorders of the eye in the United States and internationally.
Full Company Profile
Add to Portfolio
Email to a Friend
Get
Summary
for Another Symbol:
Symbol Lookup
Latest News
Canadian Indices